

Mississippi Division Of Medicaid Preferred Drug List Changes

P&T Meeting Date: August 13, 2013

PDL Changes Effective Date: October 1, 2013

The following changes will be made to the Preferred Drug List (PDL), effective October 1, 2013, pending recommendation and/or approval by the P&T Committee, DOM, and DOM's Executive Director.

For a comprehensive PDL, refer to http://www.medicaid.ms.gov/Pharmacy.aspx.

NEW PREFERRED DRUGS		
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS	
Miscellaneous Brand/Generic	alprazolam	
Miscellaneous Brand/Generic	CARAFATE SUSPENSION (sucralfate)	

NEW NON-PREFERRED DRUGS		
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS	
Antiemetics	DICLEGIS (doxylamine/pyridoxine)	
Cystic Fibrosis Agents	TOBI PODHALER (tobramycin)	
Hypoglycemics, Sodium Glucose Cotransporter-2 Inhibitors	INVOKANA (canagliflozin)	
Apolipoprotein B-100 Synthesis Inhibitor	KYNAMRO (mipomersen)	
Miscellaneous Brand/Generic	alprazolam ER	
Miscellaneous Brand/Generic	sucralfate suspension	
Multiple Sclerosis Agents	TECFIDERA (dimethyl fumarate)	
Ophthalmic Anti-Inflammatories	PROLENSA (bromfenac)	

NEW THERAPEUTIC CLASSES/DRUGS		
NEW THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS	
Antineoplastics – Selected Systemic Enzyme Inhibitors	AFINITOR (everolimus)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	BOSULIF (bosutinib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	CAPRELSA (vandetanib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	COMTRIQ (cabozantinib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	GLEEVEC (imatinib mesylate)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	ICLUSIG (ponatinib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	INLYTA (axitinib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	IRESSA (gefitinib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	JAKAFI (ruxolitinib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	NEXAVAR (sorafenib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	SPRYCEL (dasatinib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	STIVARGA (regorafenib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	SUTENT (sunitinib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	TARCEVA (erlotinib)	



Mississippi Division Of Medicaid Preferred Drug List Changes

P&T Meeting Date: August 13, 2013

PDL Changes Effective Date: October 1, 2013

NEW THERAPEUTIC CLASSES/DRUGS		
NEW THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS	
Antineoplastics – Selected Systemic Enzyme Inhibitors	TASIGNA (nilotinib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	TYKERB (lapatinib ditosylate)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	vandetanib	
Antineoplastics – Selected Systemic Enzyme Inhibitors	VOTRIENT (pazopanib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	XALKORI (crizotinib)	
Antineoplastics – Selected Systemic Enzyme Inhibitors	ZELBORAF (vemurafenib)	
Irritable Bowel Syndrome/Short Bowel Syndrome Agents	dicyclomine	
Irritable Bowel Syndrome/Short Bowel Syndrome Agents	hyoscyamine	

NEW THERAPEUTIC CLASSES/DRUGS		
NEW THERAPEUTIC CLASS	RECOMMENDED for Non-PREFERRED STATUS	
Irritable Bowel Syndrome/Short Bowel Syndrome Agents	AMITIZA (lubiprostone)	
Irritable Bowel Syndrome/Short Bowel Syndrome Agents	BENTYL (dicyclomine)	
Irritable Bowel Syndrome/Short Bowel Syndrome Agents	FULYZAQ (crofelemer)	
Irritable Bowel Syndrome/Short Bowel Syndrome Agents	GATTEX (teduglutide)	
Irritable Bowel Syndrome/Short Bowel Syndrome Agents	LEVSIN (hyoscyamine)	
Irritable Bowel Syndrome/Short Bowel Syndrome Agents	LEVSIN-SL (hyoscyamine)	
Irritable Bowel Syndrome/Short Bowel Syndrome Agents	LINZESS (linaclotide)	
Irritable Bowel Syndrome/Short Bowel Syndrome Agents	LOTRONEX (alosetron)	
Irritable Bowel Syndrome/Short Bowel Syndrome Agents	NUTRESTORE POWDER PACK (glutamine)	
Irritable Bowel Syndrome/Short Bowel Syndrome Agents	ZORBTIVE (somatropin)	

For changes in red italics, existing users as of 9-30-13 will be grandfathered